
Current Epidemiology of *Pneumocystis* Pneumonia

Alison Morris,*† Jens D. Lundgren,‡ Henry Masur,§ Peter D. Walzer,¶ Debra L. Hanson,#
Toni Frederick,# Laurence Huang,** Charles B. Beard,†† and Jonathan E. Kaplan#

Pneumocystis pneumonia (PCP) has historically been one of the leading causes of disease among persons with AIDS. The introduction of highly active antiretroviral therapy in industrialized nations has brought about dramatic declines in the incidence of AIDS-associated complications, including PCP. In the adult population, the incidence of PCP has significantly decreased, but it remains among the most common AIDS-defining infections. Similar declines have been documented in the pediatric population. In much of the developing world, PCP remains a significant health problem, although its incidence among adults in sub-Saharan Africa has been debated. This review discusses the epidemiology of PCP during the current era of the AIDS epidemic. Although fewer cases of PCP occur in industrialized countries, increasing drug-resistant HIV infections, possible drug-resistant PCP, and the tremendous number of AIDS cases in developing countries make this disease of continued public health importance.

Pneumocystis pneumonia (PCP), which is caused by *Pneumocystis jirovecii* (formerly *P. carinii* f. sp. *hominis*), is frequently the first serious illness encountered by HIV-infected persons. During the early years of the AIDS epidemic, PCP was the AIDS-defining illness for as many as two thirds of patients in the United States. Although a decline in incidence of PCP occurred during the era of highly active antiretroviral therapy (HAART), PCP remains the most common serious opportunistic illness in HIV-infected persons (1). Patients in the developing world without access to PCP prophylaxis or

antiretroviral drugs remain at high risk, and PCP continues to develop in certain groups in industrialized countries.

The drug of choice for treatment and chemoprophylaxis of PCP is trimethoprim-sulfamethoxazole (TMP-SMX). In recent years, antimicrobial drug resistance has emerged as a possible cause of failure of patients to respond to TMP-SMX. Investigators have demonstrated an association between exposure to sulfa drugs and mutations in the dihydropteroate synthase (DHPS) gene of *P. jirovecii*, but the relationship between these mutations and treatment (or prophylaxis) failure is unclear. Understanding whether DHPS mutations cause antimicrobial drug resistance is important in guiding clinicians who care for patients with PCP.

A series of articles in this issue of Emerging Infectious Diseases highlights the continuing importance of PCP, the potential for drug resistance, and laboratory techniques that can be used to study the problem. We hope that these articles will stimulate interest in exploring the relationship between DHPS mutations and resistance of *P. jirovecii* to sulfa-containing drugs and in assessing DHPS mutations as possible causes of treatment failure in patients with PCP. In this introductory article, we summarize the changes in incidence of PCP since the introduction of HAART, discuss groups at risk for PCP in developing and industrialized nations, and examine possible future trends in the disease. A data collection form has been included online with this series of articles to assist in the collection of appropriate and standardized data from patients with PCP and to facilitate comparing and pooling data from different centers (online Appendix available from http://www.cdc.gov/ncidod/eid/vol10no10/03-0985_app.pdf).

PCP before HAART

The first clinical cases of PCP were reported during World War II in orphanages in Europe. These cases of "plasma cell pneumonia" were common among malnourished children and were later reported in children in

*University of Southern California, Los Angeles, California, USA; †University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; ‡University of Copenhagen, Hvidovre, Denmark; §National Institutes of Health, Bethesda, Maryland, USA; ¶University of Cincinnati, Cincinnati, Ohio, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **University of California San Francisco, San Francisco, California, USA; and ††Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

Iranian orphanages. The disease was then recognized in patients who were immunocompromised because of malignancies, immunosuppressive therapy, or congenital immunodeficiencies. Solid organ transplantation increased the number of patients at risk for PCP, although rates diminished after chemoprophylaxis was introduced. Without chemoprophylaxis, rates of PCP are 5%–25% in transplant patients, 2%–6% in patients with collagen vascular disease, and 1%–25% in patients with cancer. Defects in CD4+ lymphocytes are a primary risk factor for developing PCP, but the immune response to *Pneumocystis* is complex. CD8+ lymphocytes seem to be important in *Pneumocystis* clearance, and defects in B-cells and antibody production may also predispose to PCP.

The beginning of the AIDS epidemic in the early 1980s shifted the incidence of PCP from a rare disease to a more common pneumonia. Clusters of PCP cases in homosexual men and intravenous drug users were one of the first indications of the HIV epidemic (2). PCP rapidly became the leading AIDS-defining diagnosis in HIV-infected patients. In the initial stages of the epidemic, PCP rates were as high as 20 per 100 person-years for those with CD4+ cell counts <200 cells/ μ L (3). PCP was responsible for two thirds of AIDS-defining illnesses, and an estimated 75% of HIV-infected patients would develop PCP during their lifetime (4).

The first substantial decline in the incidence of PCP occurred after the introduction of anti-*Pneumocystis* prophylaxis in 1989 (5). Although absolute numbers of cases of PCP as an AIDS-defining illness in the United States remained stable from 1989 to 1992 because of an increasing incidence of AIDS, the percentage of AIDS cases with PCP declined from 53% in 1989 to 49%, 46%, and 42% in 1990, 1991, and 1992, respectively (Centers for Disease Control and Prevention, AIDS Surveillance Summaries, 1989–1992). The later use of combination antiretroviral therapy further reduced the rates of PCP among adults by 3.4% per year after 1992 (1).

PCP in Adults in Industrialized Countries after HAART

Incidence

The advent of HAART has resulted in further declines in rates of PCP and other opportunistic infections (1). Several large, multicenter studies have specifically tracked the incidence and epidemiologic features of PCP. The largest is the Adult and Adolescent Spectrum of HIV Disease (ASD) Project. Data from this project indicated a marked reduction in the incidence of all opportunistic infections in 1996 and 1997, when HAART first became widely available (Figure 1). PCP cases decreased 3.4% per year from 1992 through 1995; the rate of decline of PCP increased to 21.5%

per year from 1996 through 1998 (1). Despite this improvement, PCP is still the most common AIDS-defining opportunistic infection in the United States.

The Multicenter AIDS Cohort study (MACS) has followed >5,000 homosexual men since 1984 (6). Of these, 2,195 were either HIV-infected at time of enrollment or seroconverted to HIV during the study. Opportunistic infection rates were compared for the HAART era (1996–1998) and the era of antiretroviral monotherapy (1990–1992) (7). For persons who seroconverted during the study period, the relative hazard for development of PCP from seroconversion to initial AIDS-defining opportunistic infection was 0.06 during the HAART era compared to the time of monotherapy. For those already diagnosed with AIDS, the study found a hazard of 0.16, which demonstrated a dramatically lower risk for PCP during the HAART era.

In Europe, the EuroSIDA study has followed a cohort of >8,500 HIV-infected patients. The investigators examined changes in incidence of AIDS-defining illnesses before and after HAART was introduced and found results similar to those in North America (8). PCP cases decreased over time (1994–1998). Incidence of PCP fell from 4.9 cases per 100 person-years before March 1995 to 0.3 cases per 100 person-years after March 1998 (9).

Occurrence in Relation to PCP Prophylaxis

PCP still occurs in industrialized nations despite the availability of HAART and anti-*Pneumocystis* prophylaxis.




Figure 1. Yearly opportunistic infection rates per 1,000 person-years, CDC Adult and Adolescent Spectrum of Disease Project, 1994–2001. CMV, cytomegalovirus; HAART, highly active antiretroviral therapy; KS, Kaposi's sarcoma; MAC, *Mycobacterium avium* complex; PCP, *Pneumocystis pneumonia*. Data are standardized to the population of AIDS cases reported nationally in the same year by the age, sex, race, HIV exposure mode, country of origin, and CD4+ lymphocyte count.

ASD investigated the history of prescriptions for PCP prophylaxis in HIV-infected adults in whom developed PCP from 1999 through 2001 (Figure 2). Almost 44% of PCP cases occurred in patients not receiving medical care, most of whom were probably not known to be HIV-infected. Forty-one percent of patients were prescribed prophylaxis but did not adhere to treatment, or PCP developed despite their taking medications appropriately. Possible explanations for PCP in the “breakthrough” group include the development of drug-resistant *Pneumocystis* or decreased efficacy of prophylaxis in those with low CD4+ cell counts. An additional 9.6% of patients were under medical care and should have received prophylaxis based on current recommendations, but had not been prescribed prophylaxis by their providers. Five percent of patients were under care but did not meet criteria for prophylaxis.

Risk Factors

A CD4+ cell count <200 cells/ μ L was the leading pre-HAART risk factor for PCP and remains an important risk factor in the HAART era. The risk for PCP increases exponentially the lower the CD4+ cell count is below 200 cells/ μ L (10). When patients on HAART have sustained increases in CD4+ cell counts >200 cells/ μ L, the risk for PCP decreases sufficiently to safely discontinue both primary and secondary prophylaxis (9,11). Those in whom PCP develops while on HAART typically have low CD4+




Figure 2. Classification of *Pneumocystis* pneumonia cases from 1999–2001, CDC Adult and Adolescent Spectrum of HIV Disease Project, n = 1,073.

cell levels. ASD found that the median CD4+ cell count in persons with PCP while on HAART was extremely low (29 cells/ μ L), although the count was somewhat higher than for those not on HAART (13 cells/ μ L) (1). The EuroSIDA study reported that persons on HAART in whom PCP developed had a median CD4+ cell count of 30 cells/ μ L, identical to those with PCP who were not receiving HAART (8). Patients without improvement in their CD4+ cell count despite use of HAART remain at risk for PCP, and PCP still rarely occurs in persons with CD4+ cell counts >200 cells/ μ L.

Other clinical factors such as sex, race or ethnicity, and HIV transmission category have been examined as risk factors for PCP. Men and women appear to have an equivalent risk for PCP (12). One study demonstrated that African Americans have approximately one third the risk for PCP as white persons (10), but this finding has not been replicated (12). PCP risk according to HIV transmission category is also debated. One autopsy study found that PCP was less common in intravenous drug users than in other risk groups (13). Kaplan et al. found a slightly increased risk for those men who had sex with men and were intravenous drug users, but risk was equivalent in other transmission categories (12).

Risk for *Pneumocystis* Colonization

Although PCP cases have declined, polymerase chain reaction (PCR) has led to the discovery of *Pneumocystis* DNA in asymptomatic persons. *Pneumocystis* in respiratory specimens from persons who do not have signs or symptoms of clinical infection and who do not progress to infection has been defined as colonization or subclinical carriage. Often, *Pneumocystis* DNA is detected only by PCR, and the organism is not seen on routine histochemical staining. The clinical significance of *Pneumocystis* in respiratory specimens and the viability of organisms detected only by PCR are unknown. However, colonization may be important for several reasons. *Pneumocystis* colonization may increase the risk for progression to PCP, carriers of the organism may transmit infection to others, and latent infection may lead to inflammation that is detrimental to the lung. Most healthy persons do not have detectable *Pneumocystis* in respiratory specimens, but rates of colonization may be as high as 69% in HIV-infected persons (14). Recent evidence suggests that non-HIV-infected persons may also be colonized with *Pneumocystis*, thus increasing the potential number of persons affected (15).

PCP in Children in Industrialized Countries

Incidence

Early in the HIV epidemic, PCP occurred in HIV-infected children at a rate of 1.3 cases per 100 child-years

from infancy to adolescence and was as high as 9.5 cases per 100 child-years in the first year of life (16,17). In the 1990s, pediatric HIV infection decreased, primarily as a result of improved prenatal HIV testing and use of HIV treatment to prevent vertical transmission of the virus. The Pediatric Spectrum of Disease (PSD) study found significant decreases in the rates of most opportunistic infections in HIV-infected children during the HAART era (Figure 3). PCP cases declined significantly from 1992 to 1997, with an increase in the rate of decline after 1995, presumably from HAART (1). Because widespread use of HAART for children has occurred more recently than for adults, the full effect of HAART on pediatric PCP likely has not yet been realized.

Risk Factors

The occurrence of PCP in infants does not seem to be related to the CD4+ cell count in the same manner as in adults, although it is related to the percentage of CD4+ cells and CD4+ cell counts are below normal in children <1 year of age with PCP (18). Furthermore, peak incidence of PCP occurs in infants 3–6 months of age, when HIV status may still be undetermined. Implementing recommendations to initiate PCP prophylaxis in all infants born to HIV-positive mothers decreased the incidence of the disease in the pediatric population before the advent of HAART (11). For children older than 6 years of age, the CD4+ cell count predicts disease in a manner similar to adults, and CD4+ cell counts <200 cells/ μ L are still considered an indication for prophylaxis (11).

Although HAART decreased the incidence of PCP in children, it has not eliminated the disease, mostly because of failure to identify HIV-infected mothers. PCP seems to occur early in life among HIV-infected infants, which suggests that exposure to *Pneumocystis* is common. In fact, anti-*Pneumocystis* antibodies develop in most nonimmunocompromised children in the first several years of life (19,20). A British study of children with PCP in the beginning of the HAART era found that PCP developed in 83 of 531 children with perinatally acquired HIV as their first AIDS indicator disease, which represented \approx 50% of AIDS diagnoses (21). Most of these children were <12 months of age, and 79% were born to mothers not previously diagnosed with HIV. Given that the mothers had unrecognized HIV disease, HAART would be expected to have little effect on disease incidence in this population, and improved maternal screening would be more important for disease prevention.

Risk for *Pneumocystis* Colonization

Colonization may occur at higher rates in healthy children than in healthy adults. Vargas recently documented that nested PCR was positive for *Pneumocystis* DNA in the




Figure 3. Yearly opportunistic infection rates per 1,000 HIV-infected children, CDC Pediatric Spectrum of Disease Project, 1994–2001. Bacterial, bacterial infections; CMV, cytomegalovirus; HAART, highly active antiretroviral therapy; LIP, lymphocytic interstitial pneumonia; MAC, *Mycobacterium avium* complex; PCP, *Pneumocystis pneumonia*. Incidence rates were calculated per 1,000 children at risk each year. All trends were significant at $p < 0.05$ in chi-square for trend analysis for four age groups (<1 year, 1–5 years, 6–9 years, and >10 years) except for the <1-year-old group for PCP, bacterial, and MAC.

nasopharyngeal aspirates of 32% of 74 healthy Chilean infants (20). Children dying of sudden infant death syndrome (SIDS) also have a high rate of *Pneumocystis* (51 [30%] of 171), as seen on microscopy of lung specimens (22). The role *Pneumocystis* plays in SIDS is not understood. Similar to the adult population, effects of *Pneumocystis* colonization and relationship to PCP developing or transmission of infection are not known.

PCP in the Developing World

In contrast to the dramatic improvements in the industrialized world, persons living in developing nations continue to be devastated by HIV. The World Health Organization estimates that 42 million persons were living with HIV at the end of 2002 and that 95% of these persons live in developing countries. Large portions of the populations of Southeast Asia and sub-Saharan Africa are infected with HIV, and an estimated 55 million persons will die of AIDS in sub-Saharan Africa from 2000 through 2020. HIV is also increasing in areas such as Latin America, eastern Europe, and Asia. Despite increasing efforts to supply affordable therapy to these nations, HAART is not widely available.

PCP still occurs frequently in many parts of the developing world (23). Studies from Thailand show a prevalence of 27% to 40% among HIV-infected patients treated at a university hospital clinic (24,25). Central and South

Table 1. Summary of selected studies of *Pneumocystis* pneumonia in African adults^a

Study (ref)	Site	Study period	No. patients	Population	Diagnostic sample/method	% with PCP (n)
Abouya, 1992 (30)	Cote d'Ivoire	1989	53	Died while inpatient	Autopsy lung tissue/Grocott	8 (4)
Ansari, 2002 (31)	Botswana	1997–1998	104	Died while inpatient	Autopsy lung tissue/Grocott	11 (11)
Aderaye, 2003 (32)	Ethiopia	1996	119	Symptomatic, AFB negative, outpatients	Expectorated sputum/IF	11 (13)
Batungwanayo, 1994 (33)	Rwanda	1990	111	Symptomatic, AFB negative, outpatients	BAL, Tbbx/Methenamine silver	5 (5)
Kamanfu, 1993 (34)	Burundi	1991	222	Symptomatic, hospitalized	BAL/Giemsa, IF	5 (11)
Malin, 1995 (35)	Zimbabwe	1992–1993	64	Symptomatic, hospitalized, AFB negative	BAL/Methenamine silver, diff-quick, toluidine blue-O	33 (21)
Worodria, 2003 (36)	Uganda	1999–2000	83	Symptomatic, hospitalized, AFB negative	BAL/IF	39 (32)

^aAFB, acid-fast bacilli; BAL, bronchoalveolar lavage; IF, immunofluorescence; IS, induced sputum; NPA, nasopharyngeal aspirate.

America also have a large number of PCP cases. One Brazilian study found that 55% of HIV-infected persons with respiratory complaints were diagnosed with PCP, although a small autopsy study of hospitalized Brazilian patients found only 13% to have PCP (26,27). Other studies in this region report PCP prevalence from 24% to 29%, depending on the population studied (28,29).

PCP in Adults in Africa

In contrast to the situation in many other developing regions, PCP has been thought to be rare in African adults. Several representative series are summarized in Table 1. Most early studies reported prevalence rates of 0% to 11% in HIV-infected patients (30,31,33,34), although one early study found a rate of 33% (35).

PCP might not have been commonly reported in Africa for several reasons. Limited resources for diagnosis may have led to lower estimates of PCP. Experienced laboratory personnel are required to prepare and interpret diagnostic specimens. Bronchoscopy is expensive, and induced sputum also requires specialized equipment and personnel to obtain adequate samples. Limited resources make empiric therapy of HIV-infected persons with pneumonia common, possibly leading to inaccurate estimates of the true incidence of PCP. HIV-infected African adults also have high rates of bacterial pneumonia and tuberculosis, diseases that may result in death at higher CD4+ cell counts and prevent many HIV-infected patients from reaching a stage at which they would be susceptible to PCP. Environmental factors, such as seasonal variations, might contribute to a low rate of PCP in Africa. However, high rates of anti-*Pneumocystis* antibodies among African children suggest that exposure to the organism is common (19). Regional strains may be less virulent, or the population may be more resistant, as HIV-infected African Americans have been shown to have lower PCP rates com-

pared to white Americans (10). Detailed molecular study of the organism in different parts of the world is needed to resolve these issues.

The incidence of PCP in Africa may be growing as the AIDS epidemic progresses. A recent review concluded that cases of PCP seem to have increased over time (23), but whether this increase resulted from actual changes in PCP incidence or from improved detection techniques is unclear. Some studies have reported higher rates of PCP in Africa compared to past findings (Table 1). Malin et al. studied a group of 64 hospitalized HIV-infected patients in Zimbabwe in 1995 (35). These patients had pneumonia unresponsive to penicillin, and sputum samples were smear-negative for acid-fast bacilli (AFB). All patients underwent bronchoscopy with bronchoalveolar lavage (BAL). Twenty-one (33%) of these patients had PCP. Reasons for a higher rate of PCP among these patients included use of definitive diagnosis and probable selection bias by including only patients with severe pneumonia when other diagnoses, such as tuberculosis, had been excluded. Another study examined 83 patients hospitalized with respiratory symptoms (36). All patients had sputum cultures that were negative for AFB and underwent bronchoscopy with BAL for diagnosis. Thirty-two patients (38.6%) were diagnosed with PCP. Not all studies have found high rates of PCP. Aderaye et al. reported that of 119 outpatients with respiratory symptoms and negative AFB cultures, only 11% had PCP (32). Similarly, another recent study found PCP in 11% of patients who underwent autopsy after dying as an inpatient with respiratory symptoms (31). Future research will be needed to clarify the risk for PCP in Africa.

PCP in Children in Africa

In contrast to adults, HIV-infected children in Africa have high rates of PCP. Autopsy series describe rates of

PCP from 14% to 51.3%, depending on the age group studied (Table 2). Ikeogu et al. found that in Zimbabwe, 19 (15.5%) of 122 HIV-infected children who died <5 years of age had evidence of PCP at autopsy (40). All cases except one were in infants <6 months. Another autopsy study from the early 1990s found that PCP was present in 11 (31%) of 36 HIV-infected infants but was not found in 42 HIV-infected children >15 months (41). The largest autopsy series examined 180 HIV-infected children in Zambia (38). Twenty-nine percent of the children died of PCP, making PCP the third leading cause of death overall. Among children <6 months of age, PCP was the most common cause of pneumonia, detected in 51.3%. Six of 84 HIV-negative children had evidence of PCP at autopsy. The most recent autopsy series reported that 10 (28.6%) of 35 HIV-infected children had PCP (37).

Because autopsy studies examine terminal disease, their assessment of disease prevalence might be biased. Several authors described prevalence of PCP among children in clinic or hospital settings to estimate disease frequency more accurately. Most studies reported rates higher than those in adults. Two authors found rates >40% among HIV-infected children hospitalized with pneumonia (42,43). Ruffini studied children from 2 to 24 months of age with pneumonia and found that 48.6% had PCP (43). Madhi found that in 231 episodes of pneumonia in HIV-infected children, 101 (43.7%) were due to PCP (39). PCP was most common in infants <6 months, although 35.7% of pneumonias in older children were also caused by PCP. Graham, in a smaller study of 16 cases of PCP in 93 children with HIV infection, also found that most cases of PCP occurred in infants (42). The study reporting the lowest frequency of PCP among children with pneumonia found 15 (9.9%) of 151 HIV-infected children to have PCP (44).

Four non-HIV-infected children also had PCP. The authors speculated that the lower rate of PCP in their study may have been attributable to their inability to follow negative sputum examinations with bronchoscopy.

The Future of PCP

The decline in PCP incidence in the industrialized world may be short-lived. Although current regimens are effective in treating HIV, as many as 19% of patients starting HAART will have a viral level >10,000 copies/mL after 48 weeks of treatment (45). In the EuroSIDA cohort, an increasing proportion of HIV-infected patients have been exposed to all classes of antiretrovirals, with 47% of their cohort exposed to nucleoside reverse transcriptase inhibitors, protease inhibitors, and non-nucleoside reverse transcriptase inhibitors by 2001 (45). Of those patients in the cohort with multidrug-resistant HIV who received salvage regimens, a new AIDS-defining opportunistic infection developed in 11%. Growing transmission of resistant HIV is also likely. If new drugs do not become available, the number of patients with resistant virus and opportunistic infections, including PCP, will continue to climb.

Not only is HIV developing resistance, but *Pneumocystis* may also develop resistance to standard prophylaxis and treatment regimens. Many researchers have reported mutations of *Pneumocystis* in response to use of sulfa- or sulfone-containing anti-*Pneumocystis* regimens. Whether these mutations increase the likelihood of prophylaxis or treatment failure is unclear and is reviewed in other papers in this series.

Conclusion

Despite the declines in death and disease from HIV in the United States and western Europe, PCP remains an

Table 2. Summary of selected studies of *Pneumocystis* pneumonia in African children^a

Study (ref)	Site	Study period	No. patients	Population/age	Diagnostic sample/method	% with PCP (n)
Ansari, 2003 (37)	Botswana	1997–1998	35	Died while inpatient/ 1–13 y	Autopsy lung tissue/Grocott	29 (10)
Chintu, 2002 (38)	Zambia	1997–2000	180	Died from respiratory disease/1 mo–16 y	Autopsy lung tissue/ Methenamine silver	29 (52)
Graham, 2000 (39)	Malawi	1996	93	Hospitalized for pneumonia/2 mo–5 y	NPA/IF	17 (16)
Ikeogu, 1997 (40)	Zimbabwe	1992–1993	122	Died on arrival to hospital/<5 y	Autopsy lung tissue/ Methenamine silver	16 (19)
Lucas, 2000 (41)	Côte d'Ivoire	1991–1992	78	HIV-positive undergoing autopsy, inpatient or outpatient/1 mo–12 y	Autopsy lung tissue/unknown	14 (11)
Madhi, 2002 (42)	South Africa	2000–2001	185 (231 episodes)	Hospitalized with severe pneumonia/1–38 mo	IS, NPA/IF	44 (101)
Ruffini, 2002 (43)	South Africa	1999	105	Hospitalized with severe pneumonia/2–24 mo	IS, NPA/IF	49 (51)
Zar, 2001 (44)	South Africa	1998	151	Hospitalized with pneumonia/3–16 mo	BAL, IS, NPA/ Methenamine silver, IF	10 (15)

^aBAL, bronchoalveolar lavage; IF, immunofluorescence; IS, induced sputum; NPA, nasopharyngeal aspirate.

important disease and is unlikely to be eradicated. In industrialized nations, PCP still occurs in those not yet diagnosed with HIV or not in medical care, those not receiving PCP prophylaxis, and those not taking or not responding to HAART. Resistance in HIV and *Pneumocystis* may contribute to future increases in PCP incidence. In most developing nations, AIDS patients are at high risk for PCP. In sub-Saharan Africa, the effect of disease from PCP in infants and children is high and is probably greater in adults than previously recognized. Colonization rates among both HIV-infected and non-HIV-infected populations may also be substantial. Better understanding of the epidemiology and transmission of PCP and improved efforts in prevention and treatment are needed.

Dr. Morris is a pulmonary and critical care physician at Keck School of Medicine at the University of Southern California. Her research interests include HIV-associated lung disease and the epidemiology of *Pneumocystis*.

References

- Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindgren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. *Clin Infect Dis*. 2000;30 Suppl 1:S5-14.
- Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, et al. An outbreak of community-acquired *Pneumocystis carinii* pneumonia: initial manifestation of cellular immune dysfunction. *N Engl J Med*. 1981;305:1431-8.
- Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of *Pneumocystis carinii* pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. *N Engl J Med*. 1990;322:161-5.
- Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. *J Acquir Immune Defic Syndr*. 1988;1:466-85.
- Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for *Pneumocystis carinii* pneumonia in AIDS. *JAMA*. 1988;259:1185-9.
- Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The multicenter AIDS cohort study: rationale, organization, and selected characteristics of the participants. *Am J Epidemiol*. 1987;126:310-8.
- Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. *AIDS*. 2001;15:347-55.
- Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study. *Lancet*. 2000;356:291-6.
- Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, d'Arminio Monforte A, et al. Discontinuation of *Pneumocystis carinii* pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. *Lancet*. 1999;353:1293-8.
- Stansell JD, Osmond DH, Charlebois E, LaVange L, Wallace JM, Alexander BV, et al. Predictors of *Pneumocystis carinii* pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. *Am J Respir Crit Care Med*. 1997;155:60-6.
- Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. *MMWR Recomm Rep*. 2002;51:1-52.
- Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. *J Infect Dis*. 1998;178:1126-32.
- Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K. Autopsy findings in a human immunodeficiency virus-infected population over 2 decades: influences of gender, ethnicity, risk factors, and time. *Arch Pathol Lab Med*. 2002;126:182-90.
- Huang L, Crothers K, Morris A, Groner G, Fox M, Turner JR, et al. *Pneumocystis* colonization in HIV-infected patients. *J Eukaryot Microbiol*. 2003;50 Suppl:616-7.
- Nevez G, Raccurt C, Jounieaux V, Dei-Cas E, Mazars E. Pneumocystosis versus pulmonary *Pneumocystis carinii* colonization in HIV-negative and HIV-positive patients. *AIDS*. 1999;13:535-6.
- Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. *Pediatr Infect Dis J*. 2001;20:40-8.
- Kattan M, Platzker A, Mellins RB, Schluchter MD, Chen XC, Peavy H, et al. Respiratory diseases in the first year of life in children born to HIV-1-infected women. *Pediatr Pulmonol*. 2001;31:267-76.
- Kovacs A, Frederick T, Church J, Eller A, Oxtoby M, Mascola L. CD4 T-lymphocyte counts and *Pneumocystis carinii* pneumonia in pediatric HIV infection. *JAMA*. 1991;265:1698-703.
- Wakefield AE, Stewart TJ, Moxon ER, Marsh K, Hopkin JM. Infection with *Pneumocystis carinii* is prevalent in healthy Gambian children. *Trans R Soc Trop Med Hyg*. 1990;84:800-2.
- Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, et al. Search for primary infection by *Pneumocystis carinii* in a cohort of normal, healthy infants. *Clin Infect Dis*. 2001;32:855-61.
- Williams AJ, Duong T, McNally LM, Tookey PA, Masters J, Miller R, et al. *Pneumocystis carinii* pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection. *AIDS*. 2001;15:335-9.
- Vargas SL, Ponce CA, Hughes WT, Wakefield AE, Weitz JC, Donoso S, et al. Association of primary *Pneumocystis carinii* infection and sudden infant death syndrome. *Clin Infect Dis*. 1999;29:1489-93.
- Fisk DT, Meshnick S, Kazanjian PH. *Pneumocystis carinii* pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. *Clin Infect Dis*. 2003;36:70-8.
- Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, et al. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand. *Int J Epidemiol*. 1998;27:289-95.
- Lumbiganon P, Kosalaraksa P, Loapaiboon M. Survival of children with AIDS: experience in a university hospital in northeast Thailand. *J Med Assoc Thai*. 2000;83:652-6.
- Michalany J, Mattos AL, Michalany NS, Filie AC, Montezzo LC. Acquired immune deficiency syndrome (AIDS) in Brazil. Necropsy findings. *Ann Pathol*. 1987;7:15-24.
- Weinberg A, Duarte MI. Respiratory complications in Brazilian patients infected with human immunodeficiency virus. *Rev Inst Med Trop Sao Paulo*. 1993;35:129-39.
- Pitchenik AE, Fischl MA, Dickinson GM, Becker DM, Fournier AM, O'Connell MT, et al. Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state. *Ann Intern Med*. 1983;98:277-84.

29. Mohar A, Romo J, Salido F, Jessurun J, Ponce de Leon S, Reyes E, et al. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. *AIDS*. 1992;6:467-73.
30. Abouya YL, Beaumel A, Lucas S, Dago-Akribi A, Coulibaly G, N'Dhatz M, et al. *Pneumocystis carinii* pneumonia. An uncommon cause of death in African patients with acquired immunodeficiency syndrome. *Am Rev Respir Dis*. 1992;145:617-20.
31. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, Nyirenda ST, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. *Int J Tuberc Lung Dis*. 2002;6:55-63.
32. Aderaye G, Bruchfeld J, Olsson M, Lindquist L. Occurrence of *Pneumocystis carinii* in HIV-positive patients with suspected pulmonary tuberculosis in Ethiopia. *AIDS*. 2003;17:435-40.
33. Batungwanayo J, Taelman H, Lucas S, Bogaerts J, Alard D, Kagame A, et al. Pulmonary disease associated with the human immunodeficiency virus in Kigali, Rwanda. A fiberoptic bronchoscopic study of 111 cases of undetermined etiology. *Am J Respir Crit Care Med*. 1994;149:1591-6.
34. Kamanfu G, Mlika-Cabanne N, Girard PM, Nimubona S, Mpfi B, Cishako A, et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. *Am Rev Respir Dis*. 1993;147:658-63.
35. Malin AS, Gwanzura LK, Klein S, Robertson VJ, Musvaire P, Mason PR. *Pneumocystis carinii* pneumonia in Zimbabwe. *Lancet*. 1995;346:1258-61.
36. Worodria W, Okot-Nwang M, Yoo SD, Aisu T. Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. *Int J Tuberc Lung Dis*. 2003;7:117-23.
37. Ansari NA, Kombe AH, Kenyon TA, Mazhani L, Binkin N, Tappero JW, et al. Pathology and causes of death in a series of human immunodeficiency virus-positive and -negative pediatric referral hospital admissions in Botswana. *Pediatr Infect Dis J*. 2003;22:43-7.
38. Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. *Lancet*. 2002;360:985.
39. Graham SM, Mtitimila EI, Kamanga HS, Walsh AL, Hart CA, Molyneux ME. Clinical presentation and outcome of *Pneumocystis carinii* pneumonia in Malawian children. *Lancet*. 2000;355:369-73.
40. Ikeogu MO, Wolf B, Mathe S. Pulmonary manifestations in HIV seropositivity and malnutrition in Zimbabwe. *Arch Dis Child*. 1997;76:124-8.
41. Lucas SB, Peacock CS, Hounnou A, Brattegaard K, Koffi K, Honde M, et al. Disease in children infected with HIV in Abidjan, Cote d'Ivoire. *BMJ*. 1996;312:335-8.
42. Madhi SA, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman KP. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with *Pneumocystis carinii* pneumonia. *Clin Infect Dis*. 2002;35:1120-6.
43. Ruffini DD, Madhi SA. The high burden of *Pneumocystis carinii* pneumonia in African HIV-1-infected children hospitalized for severe pneumonia. *AIDS*. 2002;16:105-12.
44. Zar HJ, Hanslo D, Tannenbaum E, Klein M, Argent A, Eley B, et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. *Acta Paediatr*. 2001;90:119-25.
45. Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. *Antivir Ther*. 2002;7:21-30.

Address for correspondence: Alison Morris, 2011 Zonal Avenue, HMR 911, Los Angeles, CA 90033, USA; fax: 323-442-2611; email: alison.morris@usc.edu

EMERGING INFECTIOUS DISEASES

Full text free online at
www.cdc.gov/eid

The print journal is available at no charge to public health professionals

YES, I would like to receive Emerging Infectious Diseases.

Please print your name and business address in the box and return by fax to 404-371-5449 or mail to

EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333

Moving? Please give us your new address (in the box) and print the number of your old mailing label here _____

**PNEUMOCYSTIS CARINII: SURVEILLANCE FOR DRUG-RESISTANCE
PCP CHART ABSTRACTION FORM**

June 24, 2004

Type of Chart Abstraction: Positive.....1
 Negative.....2

PCP study number: |_|_|_|-|_|_|_|_|_|_|-|_|_|_|

Data abstractor's ID: |_|_|_|

Hospital Name: _____

Date of chart review: |_|_|_|-|_|_|_|-|_|_|_|_|_| (MM/DD/YYYY)

Date of admission: |_|_|_|-|_|_|_|-|_|_|_|_|_| (MM/DD/YYYY)

Date of discharge: |_|_|_|-|_|_|_|-|_|_|_|_|_| (MM/DD/YYYY)

SECTION A: BACKGROUND INFORMATION

A1. Patient Date of Birth: |__|_|_| - |__|_|_|_|_| (MM/YYYY)

A2. Patient State of Birth: _____ /__/_/

If outside of the U.S., country of birth _____ /__/_/

(If unknown, code as /9/9/)

A3. State and Zip Code of Current Residence:

CITY _____

STATE _____

ZIP CODE _____

(For unknown Zip code, code as "99999")

(For homeless, code as "00000")

A4. Patient Gender (at birth): Male.....1

Female.....2

A5a. What ethnic group is the subject considered to be?

- Hispanic/Latino
- Not Hispanic/Latino
- Not Specified

A5b. What racial group is the subject considered to be?

(Other is not an option. Respondents must be instructed that they may choose more than one option)

- White
- African American or Black
- Asian
- American Indian or Alaska Native
- Native Hawaiian or other Pacific Islander
- Not Specified

A6. Was patient aware of his/her HIV infection before this admission?

Yes..... 1

No..... 2

Unknown..... 9

A7. Date of first laboratory diagnosis of HIV: |__|_|_| - |__|_|_| - |__|_|_|_|_|

MM-DD-YYYY

(Code with year only if month and day unknown. If HIV infection first documented during this hospitalization, enter date serum specimen for HIV test was drawn. If HIV infection has never been documented, leave blank.)

- A8. Indicate the reliability of information on date of HIV infection (circle one).
 Date documented in chart by previous lab report..... 1
 Date mentioned in a clinic/admission note..... 2
 Other..... 3
- A9. Indicate if the patient had a previous CD4 count documented to be <200 or had an AIDS-defining illness.
 Note to abstractors: some typical AIDS-defining illness: PCP, disseminated MAC, toxoplasmosis, microsporidiosis, thrush, CMV retinitis, chronic cryptosporidiosis, extrapulmonary TB.
- Yes..... 1
 No..... 2 (Go to A11)
 Unknown..... 9 (Go to A11)
- A10. Enter earliest date that patient had an AIDS-defining illness or CD4 count < 200.
 ____|____|____-____|____|____-____|____|____|____|
 MM - DD - YYYY
- A11. History of *Pneumocystis* pneumonia prior to this hospitalization?
 Yes..... 1
 No..... 2 (Go to next section)
 Unknown..... 9 (Go to next section)
- A12. Date of most recent PCP diagnosis ____|____|____-____|____|____-____|____|____|____|
 (MM-DD-YYYY)
- A13. This most recent PCP episode was (circle one):
 Presumptive..... 1
 Lab diagnosed 2
 Unknown..... 9
- A14. Was treatment with TMP/SMX used during this most recent PCP episode?
 Yes..... 1
 No..... 2
 Unknown..... 9

SECTION X: DIAGNOSTIC EVALUATION

X1. Sputum Induction Result (PCP)

- Positive.....1
- Negative2
- Not done.....3 (Go to X3)

X2. Sputum Induction Date | | | - | | | - | | | | | | | (MM/DD/YYYY)

X3. Bronchoalveolar lavage

- Positive.....1
- Negative2
- Not done.....3 (Go to X5)

X4. Bronchoalveolar lavage Date | | | - | | | - | | | | | | | (MM/DD/YYYY)

X5a. Additional specimen

- Sputum (go to X5b)
- Bronchoalveolar lavage (go to X5c)
- Not done (go to X6)

X5b. Additional Sputum Result

- Positive..... 1 (go to X5d)
- Negative 2 (go to X5d)

X5c. Additional Bronchoalveolar Lavage Result

- Positive..... 1 (go to X5e)
- Negative 2 (go to X5e)

X5d. Additional Sputum Specimen Date | | | - | | | - | | | | | | | (MM/DD/YYYY)

X5e. Additional Bronchoalveolar Lavage Specimen Date | | | - | | | - | | | | | | | (MM/DD/YYYY)

X6. If microscopic diagnosis of PCP made, indicate semi-quantitative result of FIRST positive specimen:

- Rare1
- Few2
- Moderate3
- Many4

- X7. If NO microscopic diagnosis of PCP made, was the subject empirically treated for PCP?
- Yes.....1
 - No.....2
 - Unknown.....9

X8. List “other” concurrent AND contributory PULMONARY diagnosis(es) during this hospitalization:

_____	_____	_____
_____	_____	_____
_____	_____	_____

SECTION B: LAB VALUES

Fill in the following table with the most recent CD4 count and viral load obtained before admission and the most recent values obtained during or after admission

B1.

CD4

Before admission _____ |__|_|__|_| - |__|_|__|_| - |__|_|__|_|__|_| |__|_|
(MM - DD - YYYY)

During/after admission _____ |__|_|__|_| - |__|_|__|_| - |__|_|__|_|__|_| |__|_|
(MM - DD - YYYY)

B2.

Viral Load
(HIV RNA)

Before admission _____ |__|_|__|_| - |__|_|__|_| - |__|_|__|_|__|_| |__|_|
(MM - DD - YYYY)

During/after admission _____ |__|_|__|_| - |__|_|__|_| - |__|_|__|_|__|_| |__|_|
(MM - DD - YYYY)

B3. Indicate type of test used to determine viral load (circle appropriate test).

- Quantitative PCR.....1
- Branch Chain DNA.....2
- NASBA.....3
- Unknown.....4

B4. Please refer to SECTION X. Skip to B5.

B5. Enter first serum LDH value that best represents the level when patient was diagnosed with PCP. Use the following guideline for selecting the best date. If the patient had at least one LDH value obtained in the 14 days before the diagnosis of PCP, enter the value for the specimen closest to the date of diagnosis. If no LDH was obtained in the 14 days before the date of PCP diagnosis, but an LDH level was obtained within 7 days after the PCP diagnosis, enter the first LDH value obtained after PCP diagnosis. If no LDH value was obtained in either of these two windows, code as "00".

LDH value	Date collected (MM – DD - YYYY)
_____	__ _ __ _ - __ _ __ _ - __ _ __ _ __ _

B6. Enter first serum albumin value obtained near PCP diagnosis date – use same criteria as for LDH.

Albumin Date collected (MM – DD - YYYY)

_____ | | | | - | | | | - | | | | | | | |

B6b. Patient weight after admission: _____ Circle one: Pounds Kilograms
Note: Record first or closest weight measured after admission.

| | | | - | | | | - | | | | | | | | (MM-DD-YYYY)

B7. Indicate amount of oxygen that was ordered for the patient when they were admitted to their hospital room (not in ER).

- Room air (no oxygen) 1
2-6 liters of oxygen by nasal canula..... 2
Oxygen by face mask 3
Patient was intubated 4
Other..... 5

Specify: _____
Unknown 9

B8. Was an arterial blood gas (ABG) obtained within 24 hours before or after admission?

- Yes..... 1
No..... 2 (Go to B13)
Unknown..... 9 (Go to B13)

B9. Date of ABG: | | | | - | | | | - | | | | | | | |
(MM - DD - YYYY)

B10. If an ABG was obtained within 24 hours, enter the results of that ABG. If no room air ABG was obtained, enter the results of first ABG.

pH _____
pCO2 _____
pO2 _____

B11. Indicate whether or not ABG was obtained on room air and, if patient was receiving supplemental oxygen, how much:

- Room air (no supplemental oxygen)..... 1 (Go to B13)
2-6 liters of oxygen by nasal canula..... 2 (Go to B13)
Oxygen by face mask 3 (Go to B13)
Patient was intubated 4 (Go to B12)
Unknown 9

B12. Deleted. Skip to B13.

B13. Was patient intubated at any time during this hospitalization?

- Yes.....1
- No.....2 (Go to B15)
- Unknown.....9 (Go to B15)

B14. First intubated on | | | - | | | - | | | | | | (MM/DD/YYYY)

Last extubated on | | | - | | | - | | | | | | (MM/DD/YYYY)

B15. Deleted. Skip to B16a.

B16a. Did patient have a pneumothorax at *admission*?

- Yes..... 1
- No..... 2
- Unknown..... 9

B16b. Did patient develop a pneumothorax at *any time during* this hospitalization?

- Yes..... 1
- No..... 2
- Unknown..... 9

B17. Date of entry to ICU: | | | - | | | - | | | | | | (MM-DD-YYYY)

Number of days in ICU: | | | | |

SECTION C: PREHOSPITALIZATION MEDICATION HISTORY

In this section, record information about medications that the patient had been prescribed and should have been taking anytime in the 3 months before being admitted to the hospital with PCP.

C1. Was patient prescribed any medication as prophylaxis for PCP?

- Yes..... 1
- No..... 2 (Go to C3)
- Unknown..... 9 (Go to C3)

C2. Check all that were prescribed and indicate dose/frequency.

PROPHYLAXIS	DOSE	Do chart notes indicate that patient might not have been taking prophylaxis prescribed? If yes, circle 'not taking as prescribed'
Trimethoprim-Sulfamethoxazole (Bactrim/Septra/Sulfatrim)		Not taking as prescribed
Pentamidine (NebuPent/Pentam-300)		Not taking as prescribed
Dapsone		Not taking as prescribed
Atovaquone (Mepron)		Not taking as prescribed
Other (Specify below)		Not taking as prescribed
Specify Name		<hr/> <hr/> <hr/>

C3. Was patient prescribed any anti-retroviral medications?

- Yes..... 1 (Continue to C4)
- No..... 2 (Go to Section D)
- Unknown..... 9 (Go to Section D)

C4.

ANTI-RETROVIRALS	DOSE	Does chart note indicate that patient might not be taking anti-retrovirals prescribed? If yes, circle 'not taking as prescribed'
AZT/ZDV/Zidovudine (Retrovir)		Not taking as prescribed
3TC/Lamivudine (Epivir)		Not taking as prescribed
AZT+3TC combo (Combivir)		Not taking as prescribed
ddI/Didanosine (Videx)		Not taking as prescribed
ddC/Zalcitabine (HIVID)		Not taking as prescribed
d4T/Stavudine (Zerit)		Not taking as prescribed
ABC/Abacavir (Ziagen)		Not taking as prescribed
Saquinavir (Invirase/Fortovase)		Not taking as prescribed
Ritonavir (Norvir)		Not taking as prescribed
Indinavir (Crixivan)		Not taking as prescribed
Nelfinavir (Viracept)		Not taking as prescribed
Amprenavir (Agenerase)		Not taking as prescribed
Tenofovir (Viread)		Not taking as prescribed
Nevirapine (Viramune)		Not taking as prescribed
Delavirdine (Rescriptor)		Not taking as prescribed
Efavirenz (Sustiva)		Not taking as prescribed
Lopinavir/Ritonavir (Kaletra)		Not taking as prescribed
AZT+3TC+ABC (Trizivir)		Not taking as prescribed
Other		Not taking as prescribed

D2. Was patient prescribed steroids (prednisone, prednisolone, solumedrol) as adjunct therapy for PCP?

- Yes..... 1
- No..... 2
- Unknown..... 9

D3. Was the patients treated with TMP/SMZ (e.g. Bactrim, Septra) at any time during hospitalization?

- Yes..... 1
- No..... 2 (Go to Section E)

D4. If yes, was treatment changed to another drug during their hospitalization?

- Yes..... 1
- No..... 2 (Go to Section E)

D5. If yes, was treatment changed due to poor response?

- Yes..... 1
- No..... 2 (Go to Section E)
- Unknown..... 9 (Go to Section E)

D6. How was poor response to therapy determined?
(Circle all that apply, then go to Section E)

- Worsening CXR or failure to improve as noted in physician's notes.....1
- Increasing or non-improving oxygen requirements.....2
- Poor clinical response.....3
 - Specify _____|_|_|
- Other.....7
 - Specify _____|_|_|
- Unknown.....9

